U.S. Markets closed

Surmodics, Inc. (SRDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.85+0.75 (+3.25%)
At close: 4:00PM EDT
People also watch

Surmodics, Inc.

9924 West 74th Street
Eden Prairie, MN 55344
United States

IndustryDiagnostic Substances
Full Time Employees219

Key Executives

Mr. Gary R. MaharajChief Exec. Officer, Pres and Director918.78k2.3M54
Mr. Andrew D. C. LaFrence CPACFO, Principal Accounting Officer and VP of Fin. & Information Systems444.55kN/A54
Mr. Bryan K. PhillipsSr. VP of Legal & HR, Gen. Counsel and Corp. Sec.493.53k44.85k46
Mr. Charles W. OlsonSr. VP of Commercial and Bus. Devel. for Medical Devices468.86k649.87k53
Mr. Joseph J. StichVP and Gen. Mang. of In-Vitro Diagnostics421.13k667.07k52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. This segment also engages in the contract research, development, and manufacture of percutaneous transluminal angioplasty balloon catheters for use in various interventional cardiology, peripheral, and other applications. The Vitro Diagnostics segment provides component products and technologies that include protein stabilization reagents, substrates, antigens, and surface coatings for diagnostic immunoassay and molecular tests, as well as to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Corporate Governance

Surmodics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 5. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 6; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.